Diabetes, Diabetes Mellitus
Conditions
Keywords
PEDF, TSP1, Thrombospondin, pigment epithelium derived factor, Wills Eye Institute, Pars plana vitrectomy, Vitreous levels, Mid Atlantic Retina, Blood draw, Blood test
Brief summary
You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.
Detailed description
The hypothesis tested here is that diabetic patients that express the higher molecular weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1) level and, as a result, are at a greater risk for the development of more severe diabetic retinopathy.
Interventions
BIOLOGICALBlood draw
3-4 tablespoons of blood will be drawn, one time.
Sponsors
MidAtlantic Retina
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Minutes to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to provide written informed consent and comply with study assessments for the full duration of the study * Diabetes Mellitus * Undergoing pars plana vitrectomy for any reason
Exclusion criteria
* Use of any anti-VEGF (vascular endothelial growth factor ) medications
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma | up to 6 months | Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease. |
Countries
United States
Outcome results
None listed